Morning all
Paul Hopper was interviewed yesterday - you can view it here:
https://www.yourmoney.com.au/watch/imugene-trading-day/
This is pitched at people who have never heard of Imugene or Immuno-therapy. He confirms a lot of what we already know - that they are looking for a partnership at Phase 2. In his last interview he talked about buy out. However this time he expresses it as "licence or sell the drug at Phase 2."
He feels their cash reserves are sufficient to take them "well into 2022." So - no financial pressure to accept a low ball offer. He also gives a good answer to why the Phase 2 trial is in Asia and Eastern Europe - not the USA. He expects the Phase 2 trial to start "hopefully in the next month or so."
My 10 cents worth on the latest addition to the SAB: Dr Caligiuri has a truly impressive CV. He won't have said "yes" without taking a good look at what IMU are doing, including the Phase 1b results. It's a strong vote of confidence from someone with serious credentials and experience. It also adds depth and breadth to IMU networks, and further credibility to the company, all of which will help when it comes to finding and signing a big Pharma partner.
Best New Year wishes
Dave
Good interview and very informative in such a short time
The hosts didnt get the difference between the B Cell platform & the current manufactured antibody solution
I am guessing that most dont .
Thus on the broader market l suspect there is broad ignorance.
There in lies the massive potential upside for IMU .....when the market finally gets it
